Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...

Discover how Treg cell therapies rethink precision medicine for autoimmune diseases like type 1 diabetes, MS, and transplant ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...

The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...